A Phase II Study of Pazopanib in the Treatment of Surgically Unresectable or Metastatic Chondrosarcoma

Inclusion Criteria:

- Written informed consent

- Age > or = to 18 years

- Histologically confirmed diagnosis of conventional chondrosarcoma of any grade

- Surgically unresectable or metastatic disease

- Any number of prior treatment regimens, including treatment naive subjects

- Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, or 2

- Measurable or evaluable (non-measurable) disease per RECIST guidelines version 1.1

- Adequate organ system function determined within 14 days prior to first dose of study
treatment

- Females must either be of non-child bearing potential or have a negative serum
pregnancy test within 7 days prior to the first dose of study treatment

Exclusion Criteria:

- Mesenchymal, dedifferentiated, and extraskeletal myxoid chondrosarcoma subtypes

- Prior malignancy (Note: subjects who have had another malignancy and have been
disease-free for 3 years, or subjects with a history of completely resected
non-melanomatous skin carcinoma or successfully treated in situ carcinoma are
eligible)

- History or clinical evidence of central nervous system metastases or leptomeningeal
carcinomatosis

- Clinically significant gastrointestinal (GI) abnormalities that may increase the risk
for GI bleeding

- Clinically significant GI abnormalities that may affect absorption of investigational
product

- Presence of uncontrolled infection

- Corrected QT interval > 480 msecs using Bazett's formula

- History of certain cardiovascular conditions within the past 6 months

- Poorly controlled hypertension [defined as systolic blood pressure of > or = 140 mmHg
or diastolic blood pressure of > or = 90 mmHg]

- History of cerebrovascular accident including transient ischemic attack, pulmonary
embolism, or untreated deep venous thrombosis within the past 6 months

- Prior major surgery or trauma within 28 days prior to the first dose of study drug
and/or presence of any non-healing wound, fracture, or ulcer

- Evidence of active bleeding or bleeding diathesis

- Known endobronchial lesions and/or lesions infiltrating major pulmonary vessels

- Hemoptysis in excess of 2.5 mL within 8 weeks of first dose of study drug

- Any serious and/or unstable pre-existing medical, psychiatric, or other condition
that could interfere with subject's safety, provision of informed consent, or
compliance to study procedures

- Unable or unwilling to discontinue use of prohibited medications for at least 14 days
prior to the first dose of study drug and for the duration of study treatment

- Radiation therapy, surgery (except major surgery), tumor embolization, chemotherapy,
immunotherapy, biologic therapy, investigational therapy, or hormonal therapy within
14 days prior to the first dose of study drug

- Any ongoing toxicity from prior anti-cancer therapy that is > Grade 1 and/or that is
progressing in severity, except alopecia